Pharvaris在ACAAI 2025上展示了支持长期安全性特征、Deucrictibant的持续益处以及Kinin生物标志物检测的临床验证数据的开放标签预防数据

• Open-label prophylaxis data supporting the long-term safety profile and sustained benefits of deucrictibant, as well as clinical validation data of a kinin biomarker assay were highlighted in two oral presentations
• Final data from participants in the open-label portion of the CHAPTER-1 study provide further evidence of a well-tolerated safety profile for up to approximately 34 months and an average of 92.4% attack reduction from study baseline with deucrictibant treatment
• Six additional posters detail the effectiveness, safety, and health-related quality of life outcomes from various clinical studies with additional evidence on deucrictibant's potentially differentiated profile in HAE

ZUG, Switzerland, Nov. 10, 2025 (GLOBE NEWSWIRE) -- Pharvaris (NASDAQ:PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to help address unmet needs of those living with bradykinin-mediated diseases such as hereditary angioedema (HAE) and acquired angioedema due to C1 inhibitor deficiency (AAE-C1INH), summarized the presentations from the 2025 Annual Meeting of the American College of Allergy, Asthma, and Immunology (ACAAI), including data from two oral presentations and six posters, which took place from November 6-10, 2025, in Orlando, Fla.